(NASDAQ:XRTX) is a late-stage clinical pharmaceutical company focused on developing innovative therapies for gout and progressive kidney disease. The company has three advanced clinical products in its pipeline: XRx-026 for gout treatment, XRx-008 for Autosomal Dominant Polycystic Kidney Disease (ADPKD), and XRx-101 for acute kidney and other organ injuries related to respiratory virus infections.
XRTX is preparing for a reverse stock split scheduled for April 6, 2026. This event will consolidate shares at a ratio of 1 new share for every 5 old shares. The consolidation was initially set for March 27, 2026, but was delayed to ensure necessary approvals from the TSX Venture Exchange and Nasdaq Stock Exchange.
The reverse stock split aims to adjust the stock price and improve its market perception. Currently, XRTX trades at $0.37, reflecting a 2.37% decrease with a $0.009 change. The stock has fluctuated between $0.35 and $0.39 today, with a 52-week high of $1.41 and a low of $0.35.
XRTX's market capitalization is approximately $515,342, with a trading volume of 47,554 shares on the NASDAQ exchange. The consolidation decision, approved by the board and shareholders, does not involve a name change for the company.
